Literature DB >> 15234476

Modulation of the NO/CO-cGMP signaling cascade during chronic morphine exposure in mice.

De-Yong Liang1, J David Clark.   

Abstract

The chronic administration of morphine and related opioid drugs results in tolerance and dependence which reduces the clinical utility of these agents. The CO/NO-cGMP signal transduction cascade plays an important role in morphine tolerance. Principal components of this pathway include heme oxygenase (HO), nitric oxide synthase (NOS), soluble guanylate cyclase (sGC) and cyclic GMP-dependent protein kinase (cGK). We measured and compared the spinal gene expression patterns of these key components using real-time PCR and Western blot analysis after chronic morphine treatment in mice. Our findings indicate that the CO/NO-cGMP signaling pathway is upregulated at multiple points after morphine exposure demonstrating a coordinated molecular and biochemical response. These findings underscore the importance of this signaling pathway in the neuroplastic events occurring during chronic opioid exposure and the value of analyzing the participation of multiple components of a signaling pathway simultaneously rather than individual members in isolation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234476     DOI: 10.1016/j.neulet.2004.04.054

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  Localization of soluble guanylyl cyclase in the superficial dorsal horn.

Authors:  Jin-Dong Ding; Richard J Weinberg
Journal:  J Comp Neurol       Date:  2006-04-20       Impact factor: 3.215

2.  Therapeutic effects of a soluble guanylate cyclase activator, BAY 60-2770, on lower urinary tract dysfunction in mice with spinal cord injury.

Authors:  Daisuke Gotoh; Tetsuichi Saito; Sergei Karnup; Yosuke Morizawa; Shunta Hori; Yasushi Nakai; Makito Miyake; Kazumasa Torimoto; Kiyohide Fujimoto; Naoki Yoshimura
Journal:  Am J Physiol Renal Physiol       Date:  2022-08-11

3.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

Review 4.  Peroxynitrite and opiate antinociceptive tolerance: a painful reality.

Authors:  Daniela Salvemini
Journal:  Arch Biochem Biophys       Date:  2008-11-11       Impact factor: 4.013

Review 5.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

6.  On the possible role of ERK, p38 and CaMKII in the regulation of CGRP expression in morphine-tolerant rats.

Authors:  Zhiyong Wang; Jean-Guy Chabot; Remi Quirion
Journal:  Mol Pain       Date:  2011-09-21       Impact factor: 3.395

7.  Formalin injection causes a coordinated spinal cord CO/NO-cGMP signaling system response.

Authors:  Xiaoyou Shi; Xiangqi Li; J David Clark
Journal:  Mol Pain       Date:  2005-11-18       Impact factor: 3.395

Review 8.  A review on hemeoxygenase-2: focus on cellular protection and oxygen response.

Authors:  Jorge Muñoz-Sánchez; María Elena Chánez-Cárdenas
Journal:  Oxid Med Cell Longev       Date:  2014-07-17       Impact factor: 6.543

9.  Morphine promotes renal pathology in sickle mice.

Authors:  Marc L Weber; Derek Vang; Paulo E Velho; Pankaj Gupta; John T Crosson; Robert P Hebbel; Kalpna Gupta
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-07-20

10.  Epigenetic regulation of spinal cord gene expression contributes to enhanced postoperative pain and analgesic tolerance subsequent to continuous opioid exposure.

Authors:  Peyman Sahbaie; De-Yong Liang; Xiao-You Shi; Yuan Sun; J David Clark
Journal:  Mol Pain       Date:  2016-04-18       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.